Uploaded on Feb 17, 2022
Efavirenz is a key drug used for treatment of Acquired Immuno Deficiency Syndrome (AIDS). It produces burning mouth syndrome which results in under dosing and plasma level fluctuations. Efavirenz also has poor solubility and resulting in poor bioavailability. The present research employed self nano emulsifying drug delivery system (SNEDDS) to provide dual benefits of taste masking and bioavailability enhancement.
Research paper MRPR
Research paper of Dr. Monica RP Rao Title: Taste evaluation by electronic tongue and bioavailability enhancement of efavirenz. Authors: Monica RP Rao, Kirti Bhutada, Pauroosh Kaushal Journal Details: AAPS PharmSciTech, (2019), 20:56. Publisher: Springer Science on behalf of American Association of Pharmaceutical Scientists Description: Efavirenz is a key drug used for treatment of Acquired Immuno Deficiency Syndrome (AIDS). It produces burning mouth syndrome which results in under dosing and plasma level fluctuations. Efavirenz also has poor solubility and resulting poor bioavailability. The present research employed self nano emulsifying drug delivery system (SNEDDS) to provide dual benefits of taste masking and bioavailability enhancement. Evaluation of taste masking is usually undertaken by testing on humans. In this study the taste masked formulation was evaluated by a unique electronic tongue apparatus by comparing with other taste standards. Pseudo ternary phase diagrams facilitated selection of oil and surfactants for the formulation viz: Capmul PG8 NF, Cremophor RH40 and Transcutol HP. The nanoemulsions had droplet size in the range of 25 to 55 nm. For taste masking studies, quinine hydrochloride was used as reference standard for bitter taste. The SNEDDS effectively reduced the burning mouth syndrome caused by the drug and also led to a 4 fold increase in bioavailability. Photographs:
Comments